E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015488 |
E.1.2 | Term | Essential hypertension |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate superior efficacy of the combination of valsartan/amlodipine 160/10 mg, in patients with stage II hypertension, by testing the hypothesis that valsartan/amlodipine 160/10 mg produces superior reduction in MSSBP from baseline compared to amlodipine 10 mg alone, at week 4 |
|
E.2.2 | Secondary objectives of the trial |
1 To compare the valsartan/amlodipine treatment strategy with the amlodipine treatment strategy in change from baseline MSSBP after 2 and 8 weeks of treatment 2 To compare the valsartan/amlodipine treatment strategy with the amlodipine treatment strategy in change from baseline MSDBP after 2, 4 and 8 weeks of treatment 3 To compare the valsartan/amlodipine treatment strategy with the amlodipine treatment strategy in the proportion of the patients reaching overall BP control ie. MSSBP 140 mmHg and MSDBP 90mmHg after 8 weeks of treatment 4 To compare a valsartan/amlodipine treatment strategy with an amlodipine treatment strategy in the incidence and severity of peripheral edema 5 To evaluate the safety and tolerability of the valsartan/amlodipine and amlodipine treatment strategies |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1 Male or female patients / 18 years of age 2 Patients must meet the following criteria prior to randomization Stage II hypertension with MSSBP / 160 mm Hg and MSSBP / 200 mm Hg at Visit 2 3 Patients must have signed and received a copy of the informed consent prior to study enrollment or any study related activities |
|
E.4 | Principal exclusion criteria |
1. Known or suspected contraindications, including history of allergy to ARBs, CCB, thiazides or to drugs with similar chemical structure 2. MSSBP 200 mmHg and/or MSDBP 120 mmHg at any time between Visit 1 and Visit 2. 3. Patients on previous antihypertensive medication who are controlled MSSBP 140 mmHg at screening visit. 4. Uncontrolled patients with more than two medication at screening visit 5. History of hypertensive encephalopathy, cerebrovascular accident. 6. History of myocardial infarction or unstable angina within 1 years prior to Visit 1 Novartis Confidential Page 12 Clinical Study Protocol Study No. CVAA489A2403 7. History of transient ischemic attack 8. Malignant hypertension 9. Evidence of a secondary form of hypertension, to include coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma 10. Known Keith-Wagener grade III or IV hypertensive retinopathy 11. Percutaneous coronary intervention PCI or coronary artery bypass graft surgery CABG within 1 years prior to Visit 1 12. Diabetes mellitus type 1 13. History of heart failure Grade II - IV according to the NYHA classification 14. Second or third degree heart block without a pacemaker 15. Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia 16. Clinically significant valvular heart disease 17. Evidence of hepatic disease as determined by one of the following ALT or AST values 3 x UNL at visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt 18. Evidence of renal impairment as determined by one of the followings serum creatinine 1.5 x UNL at visit 1, a history of dialysis, or a history of nephrotic syndrome 19. Serum sodium value 135 mmol/L at visit 1 20. Serum potassium values 3.5 mmol/L or 5.5 mmol/L at visit 1 21. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug 22. Women of child-bearing potential WOCBP , defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal 12 months of natural spontaneous amenorrhea or 6 weeks post surgical bilateral oophorectomy and/or hysterectomy OR are using one or more of the following acceptable methods of contraception surgical sterilization e.g., bilateral tubal ligation, hysterectomy , hormonal contraception implantable, patch, oral , and double barrier methods1 any double combination of IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap 23. Pregnant or nursing lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test 5 mIU/ml 24. Any surgical or medical condition which, at the discretion of the investigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period Novartis Confidential Page 13 Clinical Study Protocol Study No. CVAA489A2403 25. History of malignancy of any organ system within the past five years, treated or untreated, including leukemia and lymphoma but not basal cell skin cancer whether or not there is evidence of local recurrence of metastases 26. Any severe, life-threatening disease within the past five years 27. History of drug or alcohol abuse within the last 2 years 28. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer 29. Inability to communicate and comply with all study requirements. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This study will assess superiority of the valsartan/amlodipine combination regimen versus the amlodipine regimen |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 2 |